Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin
Authors:
- Rebecca B. LuriaRLRebecca B. Luria
- 1 June 2009
- journal article
- case report
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 60 (6) , 1037-1041
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- ScleromyxedemaMedicine, 2008
- ScleromyxedemaJournal of the American Academy of Dermatology, 2007
- Arndt–Gottron scleromyxoedema: successful therapy with intravenous immunoglobulinsBritish Journal of Dermatology, 2007
- Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulinBritish Journal of Dermatology, 2005
- Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulinsJournal of the European Academy of Dermatology and Venereology, 2005
- Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedemaJournal of the American Academy of Dermatology, 2001
- Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)Journal of the American Academy of Dermatology, 2000
- Fatal scleromyxedema: Report of a case and review of the literatureJournal of the American Academy of Dermatology, 1998
- ScleromyxedemaJournal of the American Academy of Dermatology, 1995
- The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis)Journal of the American Academy of Dermatology, 1993